Back to search

Ireland· IE-PA-EU/1/08/504/002

Firmagon 120 mg powder and solvent for solution for injection

A degarelix product containing degarelix (as acetate), registered in Ireland by Ferring Pharmaceuticals A/S. The same ATC class is registered in 16 of our 19 countries.

ATC L02BX02

Checked against HPRA (Ireland) on

Informational only — not a medical device.

SOURCE REGISTER · IEHPRA (Ireland)normalisedFirmagon 120 mg powder and solvent fo…ATCL02BX02REGISTER NO.IE-PA-EU/1/08/504/002PACKS LISTED1CHECKEDSeptember 28, 2026

Where it is registered

Degarelix is registered in 16 of 19 countries.

Countries holding a registration under ATC L02BX02 (degarelix), each read from that country’s own register.

  • This record: Ireland, from HPRA (Ireland)
  • 10 of them publish a price we can compare per daily dose

Degarelix · ATC L02BX02

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of degarelix costs, country by country.

Normalised to the WHO defined daily dose (2.7 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Degarelix · price per daily dose (2.7 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$4.90
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

HPRA (Ireland)
Active substance
Degarelix (as acetate)
Manufacturer
Ferring Pharmaceuticals A/S
Country
Ireland (IE)
ATC code
L02BX02
ATC class
Degarelix
Defined daily dose
2.7 mg, P
Reimbursed
Not published by this register
Source register
HPRA (Ireland)
Last checked
September 28, 2026

Packs & prices · 1

  • ie_pa_number
    EU/1/08/504/002

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

266 interactions on record for degarelix.

Graded by severity as the source publishes them — 71 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Degarelix · interactions on record

266 records

  • 71 severe
  • 192 moderate
  • 3 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • QuinidineC01BA01severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b915ed5e-8c49-4689-b3fb-002f6972a6f8
GET /v1/drugs/b915ed5e-8c49-4689-b3fb-002f6972a6f8?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Powder and solvent for solution for injection",
  "routes": [
    "Subcutaneous use"
  ],
  "source": "hpra",
  "atc_all": [
    "L02BX",
    "L02BX02"
  ],
  "strength": null,
  "pa_number": "EU/1/08/504/002",
  "substances": [
    "Degarelix (as acetate)"
  ],
  "legal_basis": "New active substance (Article 8(3) of Directive No 2001/83/EC)",
  "market_info": "Unknown",
  "authorised_at": null,
  "dispensing_status": "Product subject to prescription which may not be renewed (A)",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": null
}

See everything about degarelix.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.